Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-26T13:52:16.021Z Has data issue: false hasContentIssue false

Chemotherapy-Associated Steatohepatitis with Temozolomide and Dexamethasone

Published online by Cambridge University Press:  02 December 2014

Robert J.H. Miller
Affiliation:
University of Calgary, Calgary, Alberta, Canada
Xianyong Gui
Affiliation:
University of Calgary, Calgary, Alberta, Canada
Jacob C. Easaw
Affiliation:
Tom Baker Cancer Centre, Calgary, Alberta, Canada Email: [email protected]
Roger Y. Tsang
Affiliation:
Tom Baker Cancer Centre, Calgary, Alberta, Canada Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1.Goldbecker, A, Tryc, AB, Raab, P, Worthman, H, Herrmann, J, Weissenborn, K.Hepatic encephalopathy after treatment with temozolomide. J Neurooncol. 2011;103(1):1636.Google Scholar
2.Vauthey, JN, Pawlik, TM, Ribero, D, et al.Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):206572.CrossRefGoogle Scholar
3.Stravitz, RT, Sanyal, AJ.Drug-induced steatohepatitis. Clin Liver Dis. 2003;7(2):43551.Google Scholar
4.Lindor, KD, Kowdley, KV, Heathcote, J, et al.Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatol. 2004;39(3):7708.Google Scholar
5.Sanyal, AJ, Chalasani, N, Kowdley, KV, et al.Pioglitazone, vitamin E or placebo for nonalcoholic steatohepatitis. New Engl J Med. 2010;362(18):167585.CrossRefGoogle ScholarPubMed